Despite the advent of the CFTR modulator therapies, chronic respiratory infections sustained by P. aeruginosa remains a major cause of morbidity and mortality in patients with CF, driving the interest in identifying innovative antimicrobial strategies to substitute or complement antibiotic use in CF [22]. Here, CFTR is linked to cystic fibrosis.